SEC For	m 4																	
FORM 4 UNIT			UNITE	D STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					d pursuant	CHANGE to Section 16(a on 30(h) of the	a) of the S	ecuriti	es Exchan	ae Act o		_	HIP	Estima	Numbe ated av	erage burde	3235-0287 n 0.5	
1. Name and Address of Reporting Person* <u>LI WILLIAM</u> (Last) (First) (Middle)				2. Issuer Name and Ticker or Trading Symbol <u>LEAP THERAPEUTICS, INC.</u> [LPTX] 3. Date of Earliest Transaction (Month/Day/Year) 01/29/2024							5. Re (Che	ck all applie Directo Officer	ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner Officer (give title Other (specify below) below)					
C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET SUITE B1-1				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc Line) X	Form f	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person					
(Street) CAMBRIDGE MA 02141				Rule 10b5-1(c) Transaction Indication									d by More than One Reporting					
(City)	(City) (State) (Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	ole I - Nor	n-Deriva	ative Se	curities Ac	quired	, Disp	osed o	f, or B	Bene	ficially	/ Owned					
Date			Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea	Code	Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	nt (A) or (D) F		Price	Transact	ansaction(s) str. 3 and 4)			(1150. 4)	
		•				urities Acq s, warrants							Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date, Ti	ransaction ode (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date E Expiratio (Month/E	on Date		7. Title of Secu Underly Derivat (Instr. 3	urities ying tive Se	curity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	

Date

Exercisable

(1)

(D)

Expiration

01/29/2034

Date

• •	
1. The Option was grante	d pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly
installments on each of M	arch 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company

/s/ Douglas E. Onsi as attorney-01/31/2024

\$<mark>0</mark>

25,000

D

in-fact for William Li

** Signature of Reporting Person Date

Amount or Number

Shares

25,000

of

Title

Common

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

01/29/2024

Stock Option

(Right to Buy) \$2.68

Explanation of Responses:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Α

(A)

25,000

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.